The Kelly Lab, within the Molecular Imaging Innovations Institute (MI3) in the Department of Radiology at Weill Cornell Medicine, is seeking a highly motivated postdoctoral research associate. The candidate will have the opportunity to train in a stimulating, demanding and multi-disciplinary environment. The candidate will be involved from discovery through validation of novel radiolabeled imaging probes and targeted radiotherapeutics by way of developing in vitro assays and preclinical disease models and performing in vivo evaluations of candidate radiolabeled compounds in preclinical models. In addition to ongoing projects, which include the investigation of imaging biomarkers of cardiomyopathy and progression to heart failure, the group will be developing probes for imaging metabolic alterations common to a range of diseases, investigating the interplay between tumor cells, the immune system and the microenvironment, and identifying new targets for imaging and radioligand therapy. Knowledge of relevant biochemical pathways is a plus.
Validate imaging biomarkers for positron emission tomography (PET) and;
Develop delivery vectors for targeted radiotherapy using alpha- or beta-particle emitting radionuclides.
Interested applicants should send a curriculum vitae, bibliography, and statement of interests to:
The Molecular Imaging Innovations Institute (MI3): Established in 2013, MI3 is committed to the further advancement of medical imaging technologies. MI3, an inter-disciplinary institute consisting of faculty, postdoctoral associates and graduate students in physics, chemistry, biology and medicine, is dedicated to the development of imaging probes and technologies that enable us to visualize disease at the molecular level. Our experts in various platform technologies, such as: radiochemistry, nanotechnology, polymer, synthetic chemistry, optical imaging, medical physics, antibody, biology, engineering, and radiology, create innovative strategies to elucidate the biological mechanisms of health and disease. Our research emphases are in the area of translational medicine related to oncology, cardiovascular diseases, neurologic and neuropsychiatric sciences, obesity research, and infectious diseases. The developed approaches are valid in the identification of diagnostic markers, detection of early disease states, derivation of treatment planning paradigms, validation of therapeutic effect, the development of guidance systems for minimally-invasive interventional / surgical procedures and finally in the discovery of new drugs. MI3 is located in the new state of the art Belfer Research Building (BRB) in the heart of the tri-institutional campus (Weill Cornell Medicine (WCM), Memorial Sloan Kettering Cancer Center (MSKCC), and Rockefeller University) in New York City. The researchers at MI3 have unprecedented opportunities to collaborate with the scientists and clinicians at Weill Cornell Medicine, Memorial Sloan-Kettering Cancer Center, and Rockefeller University. Our collaborative environment serves as a nexus for pre-clinical and clinical translational programs. Using our unique advanced research resources, MI3 is able to fuel clinical imaging with therapeutic treatment. MI3’s mission is to drive innovation of new diagnostics and therapies from bench to bedside, and to accelerate the development and transition of personalized medicine.
WeillCornellMedicine: Founded in 1898, and affiliated with what is now New York-Presbyterian Hospital (NYPH)since 1927, Weill Cornell Medicine (WCM) is among the top-ranked clinical and medical research centers in thecountry. In addition to offering degrees in medicine, WCM also has PhD programs in biomedical research andeducation at the Weill Cornell Graduate School of Medical Sciences, and with neighboring Sloan-KetteringInstitute and The Rockefeller University, has established a joint MD-PhD program for students to intensify theirpursuit of Weill Cornell's triple mission of education, research, and patient care. WCM is divided into 24 basicscience and patient care departments that focus on the sciences underlying clinical medicine and/or encompass thestudy, treatment, and prevention of human diseases. The basic science and clinical departments are located inbuildings that straddle York Ave. between 68th and 72nd streets on Manhattan’s Upper East Side. Weill CornellMedical College has 1781 full-time faculty (3582 total faculty) distributed across 8 basic science and 15 clinicaldepartments. WCM maintains major affiliations with Memorial Sloan-Kettering Cancer Center, The RockefellerUniversity, the Hospital for Special Surgery, as well as with the metropolitan-area institutions that constitute NYPHealthcare Network.
Weill Cornell Medicine is a comprehensive academic medical center that's committed to excellence in patient care, scientific discovery, and the education of future physicians in New York City and around the world. Our doctors and scientists-faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and the Weill Cornell Physician Organization-are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side's scientific corridor, Weill Cornell Medicine's powerful network of collaborators extends to its parent university Cornell University; to Qatar, where an international campus offers a U.S. medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Our medical practices serve communities throughout New York City, and our faculty provide comprehensive care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian/Lower Manhattan Hospital, and NewYork-Presbyterian/Queens. At Weill Cornell Medicine, we work together to treat each individual, not just their conditions or illnesses, as we strive to deliver the finest possible care for our patients - the center of everything we do.
The candidate must hold a Ph.D. in a field relevant to radiopharmaceutical development (e.g. chemistry, biochemistry, biology, biomedical engineering). (S)he should be highly motivated and able to contribute to multiple projects in parallel. In addition, the candidate must be willing and physically able to work with small quantities of radiation. Prior postdoctoral experience is not required, but the candidate must have experience handling radioactive materials and in vivo disease models. Experience with various methods of compound administration, including intravenous, subcutaneous, and intraperitoneal, will be highly valued. The candidate will be expected to contribute to manuscript preparation and submission of proposals for funding.
Internal Number: JMK01
About Weill Cornell Medicine
Weill Cornell Medicine is an Equal Employment Opportunity Employer. Weill Cornell Medicine provides equal employment opportunities to all qualified applicants without regard to race, sex, sexual orientation, gender identity, national origin, color, age, religion, protected veteran or disability status, or genetic information.